<DOC>
	<DOCNO>NCT02400775</DOCNO>
	<brief_summary>The purpose study evaluate effect oral azilsartan daily 32 week coronary artery plaque essential hypertensive patient stable angina dyslipidemia .</brief_summary>
	<brief_title>A Study Evaluate Effects Azilsartan Coronary Artery Plaque Essential Hypertensive Patients With Stable Angina Dyslipidemia .</brief_title>
	<detailed_description>The open-label design without control group select clinical study primarily aim explore effect azilsartan coronary artery plaque . This study target patient coronary artery plaque design enroll hypertensive patient dyslipidemia . Also light invasive nature major assessment procedure ( i.e. , IB-IVUS , OCT ) , study enroll patient stable angina plan undergo percutaneous coronary intervention stent placement , among patient coronary artery plaque . The start dose azilsartan set 20 mg basis usual clinical dose drug patient essential hypertension , dose increase azilsartan permit target blood pressure achieve . The duration treatment set 32 week line clinical practice , coronary angiography typically perform 32-week follow-up period follow PCI stent placement .</detailed_description>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<criteria>1 . Patients essential hypertension office blood pressure start study treatment ( Week 0 ) meeting follow criterion appropriate azilsartan therapy opinion principal investigator investigator Patients age ≥ 75 year time inform consent : Sitting systolic blood pressure ≥ 150 mmHg sit diastolic blood pressure ≥ 90 mmHg Patients age &lt; 75 year time inform consent concurrently type 2 diabetes mellitus : Sitting systolic blood pressure ≥ 130 mmHg sit diastolic blood pressure ≥ 80 mmHg Patients age &lt; 75 year time inform consent concurrently chronic kidney disease ( CKD ) proteinuria : Sitting systolic blood pressure ≥ 130 mmHg sit diastolic blood pressure ≥ 80 mmHg Patients meet none : Sitting systolic blood pressure ≥ 140 mmHg sit diastolic blood pressure ≥ 90 mmHg 2 . Patients stable angina coronary stenosis confirm coronary angiography plan undergo percutaneous coronary intervention stent placement ( type stent ) 3 . Patients finding integrate backscatter intravascular ultrasound ( IBIVUS ) perform start study treatment ( Week 0 ) showing plaque ( ≥ 5 mm length ) ≥ 5 mm proximal proximal end insert stent coronary artery 4 . Patients dyslipidemia meeting follow criterion : Patients treat one HMGCoA reductase inhibitor change dosage least 12 week informed consent Patients LDLC level &lt; 100 mg/dL show laboratory test perform within 4 week inform consent 5 . Men woman age 20 old time inform consent 6 . Patients capable make outpatient study visit throughout observation period 7 . Patients , opinion principal investigator investigator , capable understanding content clinical study comply study requirement 8 . Patients capable provide write consent person study procedures 1 . Patients secondary hypertension malignant hypertension 2 . Patients take reninangiotensin system inhibitor within 12 week inform consent 3 . Patients previously underwent coronary artery bypass graft 4 . Patients type 1 diabetes mellitus 5 . Patients insulin therapy 6 . Patients HbA1c level ( National Glycohemoglobin Standardization Program [ NGSP ] value ) ≥ 7.0 % show laboratory test perform within 4 week inform consent 7 . Patients plaque unevaluable severe calcification coronary artery show IBIVUS perform start study treatment ( Week 0 ) 8 . Patients change antidyslipidemic medication ( include change dosage ) within 12 week inform consent 9 . Patients clinically evident renal disorder ( define estimate glomerular filtration rate &lt; 30 mL/min/1.73m2 ) 10 . Patients severe liver disorder 11 . Patients hyperkalemia ( define serum potassium ≥ 5.5 mEq/L ) 12 . Patients history hypersensitivity allergy azilsartan 13 . Patients participate clinical study 14 . Pregnant woman , woman possible pregnancy , breastfeed woman 15 . Other patient inappropriate participation study opinion principal investigator investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Pharmacotherapy</keyword>
</DOC>